title: Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs.
abstract: AKT inhibitors represent promising therapeutics for cancers with PI3K-AKT pathway hyperactivation. In this issue of Cancer Cell, Wang et al. (2016) report the unexpected finding that ablation of AKT signaling in hepatocytes leads to hepatocellular carcinoma and enhances the incidence of lung metastases in a toxin-induced liver cancer model.
authors.affiliation: The Campbell Family Institute for Breast Cancer Research, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Fortin
authors.affiliation: The Campbell Family Institute for Breast Cancer Research, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada; Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada. Electronic address: tmak@uhnresearch.ca.
authors.forename: Tak W
authors.initials: TW
authors.lastname: Mak
mesh_terms: D006801:Humans; D008113:Liver Neoplasms; D008175:Lung Neoplasms; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt